EQL Pharma AB is a Sweden-based Company that operates as a generic drugs and specialty pharmaceutical company. The Company engages in marketing, distributing, and selling generic drugs and specialty pharmaceuticals. Its main products are Anastrozol, Venlafaxin, Carvedilol, Metformin, Sumatriptan, Mometason, Glepark, among others. The company operates in Sweden and in Scandinavia.

Employees

Sector

Drug Retailers

Calendar

11-05 Earnings release - Q2 2027

More about the company

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

End-of-day quote NORDIC GROWTH MARKET 05/07/2024			5-day change	1st Jan Change
60.80 ^SEK	-1.62%		+8.19%	+82.04%

08-20	EQL Pharma AB Appoints Niraj Kumar as New Board Member	CI
08-17	EQL Pharma CFO Allan Sylvest Aasberg makes his first share purchase	FW

Market Cap	760M 78.48M 67.62M 64.02M 58.03M 109M 7.5B 109M 292M 3.81B 295M 288M 12.05B	P/E 2027 *	-	P/E 2028 *	10.8x
Enterprise Value	1.18B 122M 105M 99.13M 89.85M 169M 11.61B 169M 453M 5.91B 456M 446M 18.66B	EV / Sales 2027 *	2.42x	EV / Sales 2028 *	1.94x
Free-Float	42.3%	Yield 2027 *	-	Yield 2028 *	-

08-20	EQL Pharma AB Appoints Niraj Kumar as New Board Member	CI
08-17	EQL Pharma CFO Allan Sylvest Aasberg makes his first share purchase	FW
08-14	DNB Carnegie raises its justified value for EQL Pharma	FW
08-12	EQL Pharma Enters UTI Treatment License Deal in Hungary	MT
08-12	EQL Pharma: Analysguiden cuts fair value estimate to 38 kronor	FW
08-12	EQL Pharma licenses Memprex to partner in Hungary	FW
08-12	EQL Pharma AB Licenses Memprex for Sale in Hungary	CI
08-07	EQL Pharma AB, Q1 2027 Earnings Call, Aug 07, 2026
08-07	EQL Pharma AB Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
08-07	EQL Pharma swings to an operating loss, 'going through a tough period' - CEO (update)	FW
08-07	EQL Pharma swings to an operating loss, 'going through a tough period' - CEO	FW
08-07	Eql Pharma AB Provides Earnings Guidance for the Year 2026/27	CI
07-28	DNB Carnegie cuts justified value for EQL Pharma	FW

08-14	DNB Carnegie raises its justified value for EQL Pharma	FW
08-12	EQL Pharma: Analysguiden cuts fair value estimate to 38 kronor	FW
07-28	DNB Carnegie cuts justified value for EQL Pharma	FW
05-13	Aktiespararna lowers fair value for EQL Pharma to SEK 46 (77) - commissioned research	FW
05-11	DNB Carnegie lowers fair value for EQL Pharma	FW

EQL Pharma AB Stock NORDIC GROWTH MARKET

Stocks

EQL

SE0005497732

Drug Retailers

Valuation: EQL Pharma AB

Latest news: EQL Pharma AB

Last Transcript: EQL Pharma AB

Analysts' recommendations: EQL Pharma AB

Press Releases: EQL Pharma AB

Quotes and Performance

Managers and Directors: EQL Pharma AB

Other Drug Retailers

Financials

Company Profile

Quarterly revenue - Rate of surprise

08-20	Bulletin from the annual general meeting in EQL Pharma AB on 20 August 2026	AQ
08-14	EQL Pharma: Improvement emerging, confirmation needed – Q1 review	AQ
08-12	Memprex© (methenamine hippurate) license signed with partner for Hungary	AQ
08-07	EQL Pharma: Soft start as expected, guidance intact	AQ
08-07	Interim Report April - June 2026	AQ

Manager	Title	Age	Since
Axel Schörling CEO	Chief Executive Officer	40	17/08/2022
Allan Sylvest Aasberg DFI	Director of Finance/CFO	51	01/04/2026
Martin Kristofferson COO	Chief Operating Officer	48	17/08/2022

Director	Title	Age	Since
Lars Christer Fedrik Fåhraeus CHM	Chairman	61	17/08/2022
Anders Månsson CHM	Chairman	59	-
Ingrid Linda Marie Neckmar BRD	Director/Board Member	53	01/01/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EQL PHARMA AB	-1.62%	+8.19%	-	-	78.48M
JD HEALTH INTERNATIONAL INC.	+0.17%	-5.28%	-50.00%	-15.53%	14.13B
MATSUKIYOCOCOKARA & CO.	+3.52%	-0.62%	-17.32%	-10.74%	6.33B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-0.66%	-5.21%	-56.77%	-34.64%	6.22B
YIFENG PHARMACY CHAIN CO., LTD.	-0.84%	-1.83%	-12.73%	-22.10%	4.06B
NAHDI MEDICAL COMPANY	-0.55%	-1.52%	-18.58%	-39.05%	3.16B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-1.39%	-5.80%	+1.84%	-31.95%	3B
GUARDIAN PHARMACY SERVICES, INC.	-0.43%	+7.04%	+47.23%	-	2.76B
CLICKS GROUP LIMITED	-4.23%	-7.07%	-48.78%	-29.54%	2.7B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	-1.19%	+0.28%	-18.21%	-6.03%	2.49B
Average	-0.72%	-2.45%	-19.26%	-23.70%	4.99B
Weighted average by Cap.	-0.10%	-3.67%	-29.44%	-21.54%

	2027 *	2028 *
Net sales	486M 50.21M 43.26M 40.96M 37.13M 69.65M 4.8B 70.01M 187M 2.44B 189M 184M 7.71B	612M 63.21M 54.46M 51.57M 46.74M 87.69M 6.04B 88.14M 236M 3.07B 237M 232M 9.71B
Net income	-	71M 7.33M 6.31M 5.98M 5.42M 10.17M 700M 10.22M 27.3M 356M 27.52M 26.92M 1.13B
Net Debt	417M 43.04M 37.08M 35.11M 31.82M 59.7M 4.11B 60.01M 160M 2.09B 162M 158M 6.61B	430M 44.38M 38.24M 36.2M 32.82M 61.56M 4.24B 61.88M 165M 2.16B 167M 163M 6.82B